4-Hydroxyamphetamine
4-Hydroxyamphetamine (4-HA), also known as para-hydroxyamphetamine (PHA), is a psychoactive drug and research chemical belonging to the phenethylamine and amphetamine chemical classes. It acts primarily as a norepinephrine-dopamine releasing agent (NDRA) with psychoactive and stimulant properties. This compound is related to more commonly known substances such as amphetamine, methamphetamine, and 3,4-methylenedioxymethamphetamine (MDMA).
Pharmacology
4-Hydroxyamphetamine has a mechanism of action similar to other amphetamine derivatives. It works by increasing the release of neurotransmitters such as dopamine and norepinephrine in the brain, leading to stimulant effects. Additionally, 4-HA may act as a serotonin releasing agent to a lesser extent. The compound's ability to release norepinephrine and dopamine contributes to its use in scientific research to study the neurotransmitter system and potential therapeutic applications.
Medical Use
Historically, 4-Hydroxyamphetamine has been used in the form of its hydrobromide salt as a mydriatic (to dilate the pupils) and in diagnostic procedures related to the sympathetic nervous system. However, its use in clinical settings has declined due to the development of more selective agents with fewer side effects.
Legal Status
The legal status of 4-Hydroxyamphetamine varies by country, but it is often regulated due to its structural similarity to controlled substances such as amphetamine and methamphetamine. In many jurisdictions, its manufacture, possession, and distribution are restricted or banned outright.
Research
Research on 4-Hydroxyamphetamine has focused on its potential applications in neuroscience and pharmacology, particularly its effects on the neurotransmitter system. Studies have explored its use as a tool to investigate the mechanisms of neurotransmitter release and reuptake, as well as its potential therapeutic effects in treating neurological disorders. However, due to its psychoactive properties and regulatory status, research is often limited.
See Also
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD